Q1 Earnings Forecast for IONS Issued By HC Wainwright

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report released on Monday, April 7th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($1.04) per share for the quarter. HC Wainwright currently has a "Strong-Buy" rating and a $45.00 price target on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals' Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.61) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.86) EPS.

IONS has been the topic of several other research reports. Citigroup lowered their price objective on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. William Blair reaffirmed an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. BMO Capital Markets decreased their price objective on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research report on Thursday, February 20th. Redburn Atlantic began coverage on Ionis Pharmaceuticals in a research note on Monday, March 31st. They issued a "neutral" rating and a $39.00 price target for the company. Finally, Needham & Company LLC reiterated a "buy" rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $56.72.

Remove Ads

Ionis Pharmaceuticals Stock Performance

Shares of IONS stock traded down $0.17 on Thursday, hitting $28.51. The company had a trading volume of 414,060 shares, compared to its average volume of 1,509,553. The firm has a market cap of $4.53 billion, a P/E ratio of -9.38 and a beta of 0.29. Ionis Pharmaceuticals has a twelve month low of $23.95 and a twelve month high of $52.34. The company has a 50-day moving average price of $31.13 and a 200-day moving average price of $34.48. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The company had revenue of $227.00 million for the quarter, compared to the consensus estimate of $140.97 million. During the same quarter in the previous year, the firm earned $0.12 EPS. Ionis Pharmaceuticals's revenue was down 30.2% compared to the same quarter last year.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 38,843 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.65, for a total value of $1,229,380.95. Following the sale, the chief executive officer now owns 180,683 shares of the company's stock, valued at $5,718,616.95. This trade represents a 17.69 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Patrick R. O'neil sold 1,207 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total transaction of $39,046.45. Following the transaction, the executive vice president now owns 56,245 shares of the company's stock, valued at approximately $1,819,525.75. The trade was a 2.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 111,956 shares of company stock worth $3,608,439 in the last quarter. 2.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Ionis Pharmaceuticals by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company's stock worth $106,922,000 after purchasing an additional 183,814 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Ionis Pharmaceuticals by 967.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 141,917 shares of the company's stock valued at $4,961,000 after buying an additional 128,619 shares during the period. SG Americas Securities LLC increased its holdings in Ionis Pharmaceuticals by 222.5% during the 4th quarter. SG Americas Securities LLC now owns 23,927 shares of the company's stock worth $836,000 after purchasing an additional 16,508 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Ionis Pharmaceuticals during the third quarter worth about $673,000. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Ionis Pharmaceuticals by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company's stock valued at $763,000 after purchasing an additional 373 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.